Further investigation as well as targeted functional studies are needed to understand how IL-33 and IL1RL1 variants contribute to disease susceptibility in IBD, and whether presence of these polymorphic markers might have clinical therapeutic implications. This evidence concerns the gene IL1RL1 and inflammatory bowel disease.